News recently hit the headlines, in both the British Medical Journal and the media, that eczema has joined the list of conditions which are linked to heart disease and stroke.
How could that be? How is the skin so closely related to disease of the heart and blood vessels?
The type of eczema implicated is one called atopic, which means it runs in families, often affects babies and is commonly accompanied by asthma and hayfever.
SkinBioTherapeutics (LON:SBTX) is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.